Hyperglycemia

Subscribe to Selected New Research on Hyperglycemia

12250 relevant articles (550 outcomes, 1097 trials/studies) found for this Disease

Description: Abnormally high BLOOD GLUCOSE level.

Also Known As:

Hyperglycemia, Postprandial; Hyperglycemias; Hyperglycemias, Postprandial; Postprandial Hyperglycemias; Postprandial Hyperglycemia

Relationship Network

Disease Context: Research Results

Nutritional and Metabolic Diseases

Metabolic Diseases: 1406

Glucose Metabolism Disorders: 41

Hyperglycemia: 12250

Glucose Intolerance: 2790

Related Diseases

1.	Hyperinsulinism (Hyperinsulinemia)
2.	Insulin Resistance
3.	Hyperlipidemias (Hyperlipidemia)
4.	Hypoglycemia (Reactive Hypoglycemia)
5.	Type 2 Diabetes Mellitus (MODY)

Experts

1.	Kersten, Judy R: 5 articles (04/2008 - 01/2002)
2.	Warltier, David C: 5 articles (04/2008 - 01/2002)
3.	Pagel, Paul S: 5 articles (04/2008 - 01/2002)
4.	Cherrington, Alan D: 5 articles (02/2008 - 02/2002)
5.	Molitch, Mark E: 4 articles (09/2008 - 11/2006)
6.	Reece, E Albert: 4 articles (04/2008 - 09/2004)
7.	Giugliano, Dario: 4 articles (01/2008 - 04/2002)
8.	Ceriello, Antonio: 4 articles (01/2008 - 04/2002)
9.	Brownlee, M: 4 articles (11/2001 - 10/2000)
10.	DeFronzo, Ralph A: 3 articles (08/2008 - 05/2007)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Hyperglycemia:

1.	Insulin (Novolin)FDA Link 03/01/2004 - "These results also show that insulin infusion is beneficial in extremely preterm infants with transient hyperglycemia." 12/01/1988 - "Diabetic BB/OK rats, characterized by a moderate hyperglycemia and a marked decrease of pancreatic insulin content, displayed a remarkable accumulation of mononucleated cells in the endocrine pancreas. " 08/01/1978 - "Those individuals who showed the most striking improvement in tissue sensitivity to insulin actually decreased their serum insulin response to hyperglycemia; those whose improvement in tissue sensitivity was more modest showed increases in beta cell responses." 10/01/2009 - "The present study demonstrated that EA improved hyperglycemia in the fasting stage with a marked increase in plasma insulin levels. " 01/01/2004 - "The common pathway begins with preclinical beta-cell autoimmunity with progressive defect of insulin secretion, followed by onset of hyperglycemia, transient usually partial remission, and finally complete insulinopenia associated with acute and chronic complications and premature death. " Order ALL the reference details at left...
2.	Glucose (Dextrose)FDA LinkGeneric 01/01/1987 - "Since hyperglycemia was improved when adipose tissue metabolism was unaltered, GH-dependent changes occurring in other tissues, such as liver or muscle, most likely contribute to derangements of glucose metabolism in diabetes, even when GH is not elevated. " 06/01/2006 - "There was rapid improvement in hepatic glucose effectiveness following only 3 h of NA infusion (NA3h = 31 +/- 6% suppression of EGP with hyperglycemia vs. NA- = 8 +/- 7%; P<0.01) and complete restoration of glucose effectiveness after 6 h of NA (NA6h = 41 +/- 8% suppression of EGP; P = NS vs. nondiabetic subjects). " 05/01/1992 - "We conclude that a marked decrease in whole-body, muscle, and nonoxidative glucose disposal can be induced by hyperglycemia alone." 02/01/2008 - "As opposed to earlier work that suggested that hyperglycemia in the acute clinical setting may be beneficial, it now appears that lower glucose levels are associated with improved outcomes. " 10/01/2007 - "The glucose infusion rate required to maintain hyperglycemia was significantly greater in POR (8.5 +/- 0.7 mgxkg(-1)xmin(-1), final 2 h) than in either CON or HAT (6.0 +/- 0.5 or 6.7 +/- 1.0 mgxkg(-1)xmin(-1), respectively). " Order ALL the reference details at left...
3.	Streptozocin (Streptozotocin)FDA Link 09/01/1987 - "Of 22 immunomodulatory substances screened 12 were effective in modulating the course of hyperglycemia following low dose streptozotocin treatment. " 08/01/1982 - "When animals that had been cured by an intrasplenic islet implant were given three subdiabetogenic booster-doses of streptozotocin, they reverted to hyperglycemia. " 09/01/1981 - "Single "subdiabetogenic" doses of streptozotocin (SZ), when given to young male CD-1 mice, produced a delayed onset of hyperglycemia dependent on the dose of SZ and on the age of the mice. " 09/01/2009 - "In our study, we employed a streptozotocin-induced rat model of diabetes to determine changes in urinary protein profiles that occur during the initial response to the attendant hyperglycemia (e.g. " 08/01/2009 - "Significant and rapid hyperglycemia was observed at 1 wk post-streptozotocin (STZ) and persisted throughout the 5-wk study. " Order ALL the reference details at left...
4.	Blood Glucose (Blood Sugar)IBA 01/01/1982 - "We evaluated the conditions of three patients with marked hyperglycemia in whom hemichorea or ballism developed that resolved completely with normalization of the blood glucose level. " 07/01/2007 - "Despite the initial hyperglycemia (341+/-15 mg/dl), the blood glucose levels of DDC-STZ-treated mice were significantly improved within 6 weeks (185+/-12 mg/dl). " 10/01/2004 - "We tested the hypothesis that blood glucose levels are associated with brain tissue pH (pH(b)) and that the correction of hyperglycemia would result in an improvement in pH(b). " 06/01/2009 - "Therefore, the purpose of the current study was threefold: 1) Determine whether GA% is altered by acute hyperglycemia in normal dogs, simulating stress induced hyperglycemia; 2) Demonstrate that GA% does not dynamically change with diurnal variation of blood glucose concentration in diabetic dogs; and 3) Investigate whether GA% is capable of providing an index of glycemic control for 1-3 weeks in diabetic dogs as is the case with diabetic human patients. " 05/01/2009 - "Only 20% would be willing to target blood glucose below 6.1 mmol x L(-1) (110 mg x dL(-1)) in the tight control group.CONCLUSIONS: This survey suggests significant variation in the management of hyperglycemia across the UK Practice varies even among intensivists from the same unit, reflecting the fact that few units have 'an agreed written guidance in place.' The majority of intensivists would be prepared to participate in a trial of tight glycemic control." Order ALL the reference details at left...
5.	AlloxanIBA 08/01/1983 - "A significant reduction in the permanent hyperglycemia caused by alloxan (50 mg/kg, iv) was observed when NIC or MNIC was given iv at a dose of 800 mg/kg 2 hr before alloxan. " 01/01/1995 - "We evaluated the protective effects of a single low-dose whole body 60Co gamma irradiation against alloxan-induced hyperglycemia in rats. " 01/01/1991 - "These interventions eliminated CPH-induced protection from alloxan, indicating a role for CPH-induced hyperglycemia in the protective effect. " 09/01/2008 - "This study aimed to compare the effects of acute hyperglycemia in the alloxan model to normal rabbit controls on wound healing, using methods of stereology. " 01/01/2006 - "We observed that the alloxan concentrations used in this study reproduced the clinical manifestations of disease including hyperglycemia (from 116 +/- 7 mg/dl to 435 +/- 80 mg/dl) in 96 hours. " Order ALL the reference details at left...
6.	Acarbose FDA LinkGeneric 11/01/1996 - "DATA SYNTHESIS: Acarbose is effective in reducing postprandial hyperglycemia. " 11/01/2009 - "Acarbose has been shown to have a beneficial effect on postprandial hyperglycemia in diabetic patients. " 01/01/2007 - "Action of acarbose is based on local inhibition of intestinal enzyme alpha-glycosidase, what leads to diminishment of postprandial hyperglycemia peak. " 09/01/2006 - "Treatment with acarbose is helpful to prevent the increase in oxidative stress and vascular dysfunction induced by hyperglycemia." 09/01/2006 - "However, there was no difference in the cumulative rate of frank fasting hyperglycemia (29% with acarbose and 34% with placebo; P = 0.65 for survival analysis). " Order ALL the reference details at left...
7.	Glucagon (Glukagon)FDA Link 07/01/1997 - "Glucagon secretion was less suppressed in the early part of the study in IPx, which may have contributed to the excessive hyperglycemia. " 10/01/1982 - "The aim of the present study was to determine the importance of hyperglycemia in the "downregulation" of the action of glucagon. " 10/13/1975 - "These studies indicate that excessive glucagon secretion participates in the genesis of diabetic postprandial hyperglycemia. " 10/01/2008 - "Remarkably, excessive secretion of glucagon from the alpha-cells is also a major contributor to the development of diabetic hyperglycemia. " 11/01/2007 - "We recorded multichannel magnetogastrograms (MGGs) before and after intravenous administration of glucagon and subsequent modest hyperglycemia in 20 normal volunteers. " Order ALL the reference details at left...
8.	Metformin (Glucophage)FDA LinkGeneric 09/01/2009 - "In this context, we have tested, for the first time in rainbow trout, metformin, a common anti-diabetic drug, known to modify muscle and liver metabolism and to control hyperglycemia in mammals. " 08/01/2009 - "Patients using sulfonylurea had greater risk of hyperglycemia (hazard ratio [HR] 1.47 [95% CI 1.30-1.66]) compared with those initiating metformin. " 08/01/2008 - "Fatal metformin overdose presenting with progressive hyperglycemia." 07/01/2007 - "Metformin and exercise reduce muscle FAT/CD36 and lipid accumulation and blunt the progression of high-fat diet-induced hyperglycemia." 01/01/2006 - "These results suggest that metformin normalizes hyperglycemia-induced mtROS production by induction of MnSOD and promotion of mitochondrial biogenesis through the activation of AMPK-PGC-1alpha pathway." Order ALL the reference details at left...
9.	troglitazone (Rezulin)FDA Link 01/01/1998 - "This decrease of SBF was significantly improved (2.9+/-0.2 ml/min/100 g) by troglitazone treatment (approximately 220 mg/kg/day) for 7 days in STZ diabetic rats without alleviating hyperglycemia. " 03/01/1998 - "Troglitazone treatment largely prevented the hyperglycemia-induced decline in submaximal (116 +/- 7 micromol x kg(-1) x min[-1]) and maximal GDR (209 +/- 9 micromol x kg(-1) x min(-1); P < 0.05). " 04/01/1995 - "Since increased hepatic gluconeogenesis is a major cause of hyperglycemia in these diabetic animals, we evaluated the effect of long-term Troglitazone treatment on hepatic gluconeogenesis. " 11/01/1996 - "These findings clearly demonstrate that the hyperglycemia in STZ-induced diabetic rats receiving an insufficient number of islet grafts to reverse diabetes was ameliorated by troglitazone treatment." 09/01/1996 - "Troglitazone treatment did not attenuate the insulinopenia and hyperglycemia of diabetic rats, but it partially improved the hypertriglyceridemia. " Order ALL the reference details at left...
10.	C-PeptideIBA 10/01/1990 - "As observed before, a remission could be obtained in most of the patients (65%) in association with a shorter duration of symptoms, less severe hyperglycemia, lower incidence of ketoacidosis, and higher plasma C-peptide concentrations. " 03/01/2009 - "This diabetic group showed hyperglycemia, and a very low level of C-peptide. " 12/01/2008 - "However, the mechanisms underlying the beneficial activity of C-peptide on the vasculature in conditions of hyperglycemia are largely unknown. " 03/27/2007 - "Human C-peptide was detected in transplanted mice concomitant with the reduction in hyperglycemia. " 11/01/2004 - "In summary, we found that prolonged mild hyperglycemia results in a compensatory increase in C-peptide secretion, which is partially mediated by an induction in vagal efferent activity." Order ALL the reference details at left...

Therapies and Procedures

1.	Transplants (Transplant) 01/01/1995 - "Immunofluorescence for GLUT2 was dramatically reduced in the beta-cells of grafts with 200 islets exposed to hyperglycemia. " 01/01/2005 - "Graft of microencapsulated SC+ neonatal porcine islets versus encapsulated islets alone resulted in significantly longer remission of hyperglycemia in NOD mice. " 01/01/1991 - "The diagnosis of rejection based on the IPF resulted in significantly greater specificity and an earlier prediction time compared with UA alone (2.4 +/- 0.3 vs 1.6 +/- 0.2 days); the IPF permitted the successful prediction of rejection 3 or more days prior to hyperglycemia in 6 of 12 (50%) grafts, whereas only 1 of 12 (8%) rejection episodes was successfully predicted when the rejection criterion was based on UA. " 01/01/1990 - "In contrast, function of intrasplenic islets was more durable with delayed onset of hyperglycemia observed in only two of six grafts at 13 and 18 months. " 06/18/1999 - "The efficacy of pancreatic islet transplants in correcting hyperglycemia and slowing the progression of complications in diabetics has been confirmed by many experimental and clinical studies. " Order ALL the reference details at left...
2.	Transplantation (Transplant Recipients) 04/01/2009 - "DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a retrospective, observational study to characterize the prevalence and assess the pharmacologic management of hyperglycemia in kidney transplant recipients who underwent transplantation at our center between June 1999 and December 2006. " 10/01/2007 - "CONCLUSIONS: Regarding findings of our study and previous studies we conclude that renal transplant recipients who develop hyperglycemia during their early post transplantation period should receive higher amount of attention over their follow up periods." 08/27/2009 - "CONCLUSIONS: These data reveal that islet beta cells from aged mice can replicate in response to hyperglycemia after transplantation at a capacity and frequencies not significantly different than that of the young adult ones." 04/01/2009 - "Prospective studies are needed to delineate factors that contribute to development of new-onset diabetes after transplantation among patients with transient hyperglycemia." 03/01/2009 - "beta TC-tet cells transduced with gp19K and RID alpha/beta lentivectors, but not with a control lentivector, provided prolonged correction of hyperglycemia after transplantation into diabetic BALB/c severe combined immunodeficient mice reconstituted with allogeneic immune effector cells or into diabetic allogeneic BALB/c mice. " Order ALL the reference details at left...
3.	Drug Therapy (Chemotherapy) 01/01/2005 - "Nevertheless, continued improvement in DES delivery as well as optimal adjunctive pharmacotherapy and control of hyperglycemia will be required to achieve the best clinical outcomes following PCI with DES in patients with diabetes." 08/01/2002 - "The time point at which medication should be added to improved health care and management changes is not currently known, but loss of body condition and development of hyperglycemia suggest more advanced PPID that would likely benefit from drug therapy. " 03/01/1987 - "Tumour pH under induced hyperglycemia and efficacy of chemotherapy." 12/01/2005 - "The purpose of this study was to examine the incidence of and risk factors for transient hyperglycemia during induction chemotherapy in Hispanic pediatric patients diagnosed with B-Precursor ALL. " 10/01/2009 - "Pharmacotherapy of hyperglycemia." Order ALL the reference details at left...
4.	Oral Administration 11/24/2000 - "In db/db mice, oral administration of compound 2 elicited significant correction of hyperglycemia. " 09/21/2000 - "It activated IRTK with an EC(50) of 300 nM and did not induce the activation of closely related receptors (IGFIR, EGFR, and PDGFR) at concentrations up to 30 000 nM. Oral administration of the compound to hyperglycemic db/db mice (0.1-10 mg/kg/day) elicited substantial to nearly complete correction of hyperglycemia in a dose-dependent manner. " 01/01/1999 - "A dose-dependent reduction of hyperglycemia (10%, 15%, 28%, and 66%) was found in db/db mice after the fifth oral administration of 3, 10, 30, and 100 mg/kg/d. " 04/15/1984 - "A single oral administration of TPTOH produced marked hyperglycemia and triglyceridemia in rabbits and hamsters, but no evidence of diabetes was found in mice, rats and guinea-pigs. " 09/01/1981 - "The mechanisms of hyperglycemia induced by an oral administration of As2O3 were investigated in treated and non-treated rats. " Order ALL the reference details at left...
5.	Length of Stay 04/01/2009 - "DISCUSSION: Age, hyperglycemia and length of stay in hospital influenced outcome from convulsive SE in the local population with hyperglycemia being a novel prognostic marker. " 04/01/2009 - "Univariate analyses revealed age (p=0.01, OR 1.075, 95% CI 1.030-1.122), length of stay in ICU (p=0.03, OR 1.299, 95% CI 1.014-1.665) and hospital (p=0.014, OR 1.203, 95% CI 1.038-1.393) and hyperglycemia (p=0.045, OR 1.327, 95% CI 1.007-1.750) associated with poor outcome. " 05/15/2007 - "The expected course of treatment, anticipated length of stay, and preadmission glycemic control influence the aggressiveness of therapy to manage hyperglycemia. " 07/01/2006 - "RESULTS: Associations exist between hyperglycemia, length of stay, and hospital costs. " 01/01/2006 - "CONCLUSIONS: Hyperglycemia after SAH is associated with serious hospital complications, increased intensive care unit length of stay, and an increased risk of death or severe disability." Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Hyperglycemia

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 550 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>